🔥 Metabolic & Weight Loss
14 peptides in this category
Adipotide
Adipotide is a targeted peptidomimetic agent designed to induce fat loss by selectively disrupting the vasculature of white adipose tissue. It functions by binding to prohibitin receptors on blood vessels supplying fat cells, triggering apoptosis and subsequent fat mass reduction. In preclinical trials, it has demonstrated significant reductions in body weight and improvements in insulin sensitivity. Due to its pro-apoptotic mechanism and potential renal toxicity, Adipotide is typically used in short-term cycles under clinical supervision.
Standard dose: 3 mg/kg SubQ daily for 2–4 weeks.
5-Amino-1MQ
5-Amino-1MQ is a lipophilic small molecule that inhibits the enzyme NNMT, enhancing energy metabolism and promoting fat loss while preserving lean muscle. Preclinical studies show notable effects on adipose tissue, cholesterol reduction, and enhanced mitochondrial function. It is being explored in preclinical models for potential fat loss and metabolic modulation.
Typical dose: 50–150 mg orally daily with food for 20–30 days, followed by 1–2 weeks off.
AICAR
AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) is a nucleotide analog and AMPK agonist that mimics cellular energy stress, leading to enhanced fat oxidation, glucose uptake, and endurance capacity. It has been studied in metabolic and athletic contexts for its ability to trigger exercise-like effects without physical activity. AICAR is also used experimentally for improving mitochondrial function and insulin sensitivity. Best suited for short-term cycles with careful monitoring to avoid over-activation of AMPK. All data is based on animal or cellular models.
Standard dose: 50 mg/kg IV once daily, typically pre-exercise or in morning.
AOD-9604
AOD-9604 is a modified peptide fragment of human growth hormone designed to stimulate fat metabolism while avoiding the adverse effects associated with hGH therapy. It promotes lipolysis, inhibits fat formation, and has a proven safety profile in human studies. It has been explored in clinical research for obesity and metabolic modulation.
500 mcg SubQ daily or 1 mg oral troche, taken in the morning on an empty stomach for 8–12 week cycles.
Cagrilintide
Cagrilintide is a novel, long-acting amylin analogue developed for weight loss and metabolic support. It works by mimicking the hormone amylin, enhancing satiety and reducing caloric intake. Clinical trials have demonstrated robust weight reduction, especially when co-administered with semaglutide. Still investigational, it shows promise in future obesity pharmacotherapy pipelines. It is often combined with GLP-1 agonists in research settings for additive effects on satiety
Start at 0.25 mg SQ weekly, titrate to 1.2 mg → 2.4 mg → 4.5 mg based on tolerance. Standard maintenance: 2.4 mg weekly. Phase 3 trials tested up to 4.5 mg for advanced weight management. Often paired with semaglutide (CagriSema protocol).
Exenatide
Exenatide is a GLP-1 receptor agonist approved for type 2 diabetes treatment. It mimics incretin hormones to stimulate insulin secretion in a glucose-dependent manner, suppresses glucagon, delays gastric emptying, and aids in weight reduction. Available in twice-daily and weekly extended-release formulations, it also shows potential benefits in hepatic fat reduction and neuroprotection.
Start with 5 mcg SubQ twice daily before meals; increase to 10 mcg if tolerated. For extended-release, 2 mg once weekly.
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist developed for obesity and metabolic disorders. It improves glucose metabolism, increases satiety, reduces food intake, and promotes significant weight loss. Clinical studies have shown strong efficacy in reducing body weight and visceral fat, with ongoing trials exploring long-term cardiovascular and endocrine benefits. Developed by Innovent Biologics, it has shown promising results in early clinical trials in China
Start at 2 mg SQ weekly for 2–4 weeks, then titrate to 4 mg → 6 mg → 9 mg based on GI tolerance. Standard maintenance: 6 mg weekly. Clinical trials tested up to 9 mg weekly for advanced weight management. Monitor glucose, lipids, renal function, and thyroid markers.
Retatrutide
Retatrutide is a next-generation triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed for potent weight loss and metabolic enhancement. It significantly improves body composition, glycemic control, and metabolic rate through synergistic mechanisms affecting appetite regulation, insulin sensitivity, and energy expenditure. Retatrutide is currently under clinical evaluation for obesity and type 2 diabetes management, demonstrating superior efficacy compared to GLP-1 monotherapies like Semaglutide or Tirzepatide. It is currently undergoing Phase II/III clinical trials for obesity and type 2 diabetes.
starts at 4 mg once weekly via subcutaneous injection to assess tolerance, then increases to 8–12 mg weekly based on response, with 12 mg being the upper clinical limit used for fat loss and metabolic benefits.
Setmelanotide
Setmelanotide is an FDA- and EMA-approved MC4R (melanocortin 4 receptor) agonist used for the treatment of genetic obesity syndromes such as POMC, LEPR, or PCSK1 deficiency. It acts centrally to restore appetite regulation and reduce hyperphagia, leading to significant weight loss in responsive populations. It is considered one of the first targeted obesity treatments based on melanocortin biology and is being explored for broader metabolic use.
Standard dose: 2 mg SubQ daily, titrated from 1–3 mg based on response and tolerance.
Survodutide
Survodutide is an investigational dual GLP-1/glucagon receptor agonist developed for obesity, MASH (Metabolic Associated Steatohepatitis), and cirrhosis. It promotes significant weight loss, improves liver markers, reduces visceral adiposity, and increases energy expenditure. Human trials report robust reductions in body weight and promising outcomes in liver disease settings. Developed by Boehringer Ingelheim, it is currently in clinical trials.
2.4 mg SubQ once weekly, titrated up from 0.6 mg as tolerated over 4–8 weeks.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor (SNDRI) studied for appetite suppression and weight loss. Originally developed for neurodegenerative diseases, it showed significant weight reduction in clinical trials for obesity.
Standard dose: 0.5 mg orally once daily.
Tesamorelin
Tesamorelin is a synthetic analog of GHRH, FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. It stimulates endogenous GH secretion, leading to significant reductions in visceral adipose tissue (VAT) and improvements in body composition. Outside this use, it has been studied in research settings for its effects on growth hormone release, body composition, and metabolic function. In research settings when stacked with Ipamorelin or GHRP-based peptides, it creates sustained GH elevation with improved metabolic outcomes.
Standard dose: 2 mg SubQ daily for 4–6 weeks.
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist peptide that provides powerful metabolic regulation for obesity and diabetes. Marketed as Mounjaro and Zepbound, it outperforms GLP-1 monotherapies in weight loss and glycemic control, and is under ongoing investigation for cardiometabolic risk reduction.
Start at 2.5 mg once weekly, titrate every 4 weeks to 5–15 mg as tolerated. Full cycles run 12–24 weeks.
Semaglutide
Semaglutide is a long-acting GLP-1 receptor agonist peptide used for weight management and glycemic control. It reduces appetite and caloric intake while enhancing insulin secretion and delaying gastric emptying. Available as Ozempic (for diabetes) and Wegovy (for obesity), it is a proven tool in treating metabolic syndrome and aiding fat loss when combined with lifestyle interventions.
0.25 mg weekly for 4 weeks, titrated upward every 2–4 weeks to a maximum of 2.4 mg weekly.